Elemer Piros
Stock Analyst at LUCID CAPITAL MARKETS
(3.16)
# 1,142
Out of 5,139 analysts
95
Total ratings
38.78%
Success rate
16.53%
Average return
Main Sectors:
Stocks Rated by Elemer Piros
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| XOMA XOMA Royalty | Initiates: Buy | $76 | $26.37 | +188.21% | 1 | Dec 9, 2025 | |
| SAVA Cassava Sciences | Initiates: Buy | $8 | $2.04 | +292.16% | 2 | Oct 6, 2025 | |
| BTAI BioXcel Therapeutics | Reiterates: Buy | $66 | $1.84 | +3,486.96% | 2 | Jul 15, 2025 | |
| FBLG FibroBiologics | Initiates: Buy | $12 | $0.33 | +3,483.16% | 1 | Dec 12, 2024 | |
| THAR Tharimmune | Initiates: Buy | $17 | $2.92 | +482.19% | 1 | Dec 6, 2024 | |
| QNCX Quince Therapeutics | Initiates: Buy | $11 | $3.55 | +209.86% | 1 | Oct 29, 2024 | |
| MNPR Monopar Therapeutics | Initiates: Buy | $50 | $70.00 | -28.57% | 6 | Oct 11, 2024 | |
| MIRA MIRA Pharmaceuticals | Initiates: Buy | $17 | $1.46 | +1,064.38% | 1 | Sep 30, 2024 | |
| CGTX Cognition Therapeutics | Reiterates: Buy | $14 | $1.46 | +858.90% | 1 | Jul 2, 2024 | |
| ANVS Annovis Bio | Reiterates: Buy | $67 | $2.89 | +2,218.34% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $43 | $17.17 | +150.44% | 1 | Jun 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.28 | +320.56% | 7 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $7.5 | $1.04 | +621.15% | 3 | Sep 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $15 | $3.64 | +312.09% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $38 | $7.35 | +417.01% | 9 | Aug 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $40 | $0.93 | +4,221.05% | 2 | Jul 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $50 | $6.19 | +707.75% | 5 | Jun 30, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $200 | $5.05 | +3,860.40% | 6 | Jun 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $33 | $16.99 | +94.23% | 3 | Mar 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $40 | $19.94 | +100.60% | 7 | Apr 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $1.15 | +3,117.39% | 1 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $32 | $7.58 | +322.44% | 2 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $77 | $7.29 | +956.24% | 2 | Dec 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $8.32 | - | 5 | Sep 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $24 → $50 | $63.84 | -21.68% | 5 | Nov 19, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $33 | $4.63 | +612.74% | 2 | Oct 22, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $15.63 | - | 3 | Jul 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $26 | $12.01 | +116.49% | 3 | May 6, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $285.04 | -90.18% | 1 | Sep 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $525 → $850 | $5.25 | +16,090.48% | 1 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $35 → $21 | $11.27 | +86.34% | 2 | Jul 12, 2017 |
XOMA Royalty
Dec 9, 2025
Initiates: Buy
Price Target: $76
Current: $26.37
Upside: +188.21%
Cassava Sciences
Oct 6, 2025
Initiates: Buy
Price Target: $8
Current: $2.04
Upside: +292.16%
BioXcel Therapeutics
Jul 15, 2025
Reiterates: Buy
Price Target: $66
Current: $1.84
Upside: +3,486.96%
FibroBiologics
Dec 12, 2024
Initiates: Buy
Price Target: $12
Current: $0.33
Upside: +3,483.16%
Tharimmune
Dec 6, 2024
Initiates: Buy
Price Target: $17
Current: $2.92
Upside: +482.19%
Quince Therapeutics
Oct 29, 2024
Initiates: Buy
Price Target: $11
Current: $3.55
Upside: +209.86%
Monopar Therapeutics
Oct 11, 2024
Initiates: Buy
Price Target: $50
Current: $70.00
Upside: -28.57%
MIRA Pharmaceuticals
Sep 30, 2024
Initiates: Buy
Price Target: $17
Current: $1.46
Upside: +1,064.38%
Cognition Therapeutics
Jul 2, 2024
Reiterates: Buy
Price Target: $14
Current: $1.46
Upside: +858.90%
Annovis Bio
Jul 2, 2024
Reiterates: Buy
Price Target: $67
Current: $2.89
Upside: +2,218.34%
Jun 21, 2024
Initiates: Buy
Price Target: $43
Current: $17.17
Upside: +150.44%
Jun 13, 2024
Initiates: Buy
Price Target: $18
Current: $4.28
Upside: +320.56%
Sep 14, 2023
Maintains: Buy
Price Target: $12 → $7.5
Current: $1.04
Upside: +621.15%
Aug 9, 2023
Reiterates: Buy
Price Target: $15
Current: $3.64
Upside: +312.09%
Aug 3, 2023
Reiterates: Buy
Price Target: $38
Current: $7.35
Upside: +417.01%
Jul 10, 2023
Reiterates: Buy
Price Target: $40
Current: $0.93
Upside: +4,221.05%
Jun 30, 2023
Reiterates: Buy
Price Target: $50
Current: $6.19
Upside: +707.75%
Jun 20, 2023
Maintains: Buy
Price Target: $260 → $200
Current: $5.05
Upside: +3,860.40%
Mar 2, 2023
Reiterates: Buy
Price Target: $33
Current: $16.99
Upside: +94.23%
Apr 14, 2022
Downgrades: Sell
Price Target: $40
Current: $19.94
Upside: +100.60%
Dec 1, 2021
Initiates: Buy
Price Target: $37
Current: $1.15
Upside: +3,117.39%
Jun 30, 2021
Maintains: Buy
Price Target: $38 → $32
Current: $7.58
Upside: +322.44%
Dec 23, 2020
Downgrades: Sell
Price Target: $77
Current: $7.29
Upside: +956.24%
Sep 8, 2020
Downgrades: Neutral
Price Target: n/a
Current: $8.32
Upside: -
Nov 19, 2019
Maintains: Neutral
Price Target: $24 → $50
Current: $63.84
Upside: -21.68%
Oct 22, 2019
Assumes: Overweight
Price Target: $33
Current: $4.63
Upside: +612.74%
Jul 11, 2019
Upgrades: Overweight
Price Target: n/a
Current: $15.63
Upside: -
May 6, 2019
Initiates: Overweight
Price Target: $26
Current: $12.01
Upside: +116.49%
Sep 11, 2018
Initiates: Overweight
Price Target: $28
Current: $285.04
Upside: -90.18%
Oct 12, 2017
Maintains: Overweight
Price Target: $525 → $850
Current: $5.25
Upside: +16,090.48%
Jul 12, 2017
Maintains: Overweight
Price Target: $35 → $21
Current: $11.27
Upside: +86.34%